British Journal of Haematology

Article	Citations
Thromboembolic risk and anticoagulant therapy in COVID‐19 patients: emerging evidence and call for action	345
COVID19 coagulopathy in Caucasian patients	260
Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID‐19) infected patients	249
Association between ABO blood groups and risk of SARS‐CoV‐2 pneumonia	241
Autoimmune haemolytic anaemia associated with COVID‐19 infection	228
Severe COVID‐19 infection and thrombotic microangiopathy: success does not come easily	150
Changes in blood coagulation in patients with severe coronavirus disease 2019 (COVID‐19): a meta‐analysis	129
Survival study of hospitalised patients with concurrent COVID‐19 and haematological malignancies	127
COVID‐19‐associated immune thrombocytopenia	126
Persisting SARS‐CoV‐2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature	117
COVID‐19 and ABO blood group: another viewpoint	98
Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID‐19): evidence of acute and sustained endothelial cell activation	89
SARS‐CoV‐2‐induced remission of Hodgkin lymphoma	89
Simultaneous onset of COVID‐19 and autoimmune haemolytic anaemia	88
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma	88
The association between severe COVID‐19 and low platelet count: evidence from 31 observational studies involving 7613 participants	85
Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiving systemic anti‐ca	84
Practical guidance for the management of adults with immune thrombocytopenia during the COVID‐19 pandemic	82
Azacitidine for patients with Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry	81
Poor outcome and prolonged persistence of SARS‐CoV‐2 RNA in COVID‐19 patients with haematological malignancies; King's College Hospital experience	81
Is molecular mimicry the culprit in the autoimmune haemolytic anaemia affecting patients with COVID‐19?	80
COVID‐19 infection in patients with sickle cell disease	78
Increased CD95 (Fas) and PD‐1 expression in peripheral blood T lymphocytes in COVID‐19 patients	78
Updates on targeted therapies for acute myeloid leukaemia	76
Clinical outcome of coronavirus disease 2019 in haemato‐oncology patients	75

Acute aorto‐iliac and mesenteric arterial thromboses as presenting features of COVID‐19	73
T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies	71
Disseminated intravascular coagulation: epidemiology, biomarkers, and management	68
Exacerbation of immune thrombocytopenia following COVID‐19 vaccination	67
Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations	66
Dynamic relationship between D‐dimer and COVID‐19 severity	65
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma	64
Clinical characteristics, management and outcome of COVID‐19‐associated immune thrombocytopenia: a French multicentre series	64
Impact of COVID‐19 on red blood cell rheology	64
Machine learning and artificial intelligence in haematology	62
Hemophagocytic lymphohistiocytosis‐like toxicity (carHLH) after CD19‐specific CAR T‐cell therapy	62
Chimeric antigen receptor (CAR) natural killer (NK)‐cell therapy: leveraging the power of innate immunity	61
Guidelines on the use of irradiated blood components	61
COVID‐19 infection and sickle cell disease: a UK centre experience	60
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia	60
Emicizumab treatment and monitoring in a paediatric cohort: real‐world data	58
Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID‐19	57
More on COVID‐19 coagulopathy in Caucasian patients	57
Prevalence of venous thromboembolism in critically ill patients with COVID‐19	56
Molecular profiling in diffuse large B‐cell lymphoma: why so many types of subtypes?	54
Endothelial cell function and endothelial‐related disorders following haematopoietic cell transplantation	54
Clinical outcomes and risk factors for severe COVID‐19 in patients with haematological disorders receiving chemo‐ or immunotherapy	54
COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies	54
First COVID‐19 maternal mortality in the UK associated with thrombotic complications	54
Successful treatment‐free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells	52
Delayed‐phase thrombocytopenia in patients with coronavirus disease 2019 (COVID‐19)	48
COVID‐19 mortality in patients on anticoagulants and antiplatelet agents	48
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic mye	48
Serological SARS‐CoV‐2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID‐19 vaccine in haematological and oncological patients	47
COVID‐19‐induced endotheliitis: emerging evidence and possible therapeutic strategies	47
Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising ant	46
Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID‐19	46
Immunogenicity and safety of the BNT162b2 mRNA COVID‐19 vaccine in haematopoietic stem cell transplantation recipients	46
Experience with provisional WHO‐entities large B‐cell lymphoma with IRF4‐rearrangement and Burkitt‐like lymphoma with 11q aberration in paediatric patients of the NHL‐BFM group	46
Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B	46
Efficacy of therapeutic plasma exchange in severe COVID‐19 patients	46
Inhibition of Band 3 tyrosine phosphorylation: a new mechanism for treatment of sickle cell disease	45
Vacuoles in neutrophil precursors in VEXAS syndrome: diagnostic performances and threshold	44
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma	44
ABO phenotype and death in critically ill patients with COVID‐19	44
Vaccine‐induced immune thrombotic thrombocytopenia (VITT) – a novel clinico‐pathological entity with heterogeneous clinical presentations	43
Early mortality benefit with COVID‐19 convalescent plasma: a matched control study	42
Genotype–phenotype correlation in children with hereditary spherocytosis	42
Non‐myeloablative human leukocyte antigen‐matched related donor transplantation in sickle cell disease: outcomes from three independent centres	41
A national service for delivering CD19 CAR‐Tin large B‐cell lymphoma – The UK real‐world experience	41
Cold agglutinin autoimmune haemolytic anaemia associated with novel coronavirus (COVID‐19)	41
COVID‐19 and immunothrombosis: emerging understanding and clinical management	41
Convalescent plasma for persisting COVID‐19 following therapeutic lymphocyte depletion: a report of rapid recovery	41
Protecting vulnerable patients with inherited anaemias from unnecessary death during the COVID‐19 pandemic	41
MYD88 L265P mutation and interleukin‐10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a pros	41

Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study	39
Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre	38
Evans syndrome in a patient with COVID‐19	38
Secondary HLH is uncommon in severe COVID‐19	37
Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis	37
Re The source of elevated plasma D‐dimer levels in COVID‐19 infection	37
Clinical outcome and prognostic factors of patients with Richter syndrome: real‐world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)	37
Haemophagocytic lymphohistiocytosis and Epstein–Barr virus: a complex relationship with diverse origins, expression and outcomes	37
Graft‐versus‐host disease risk after chimeric antigen receptor T‐cell therapy: the diametric opposition of T cells	36
COVID‐19 in bone marrow transplant recipients: reflecting on a single centre experience	36
Terminal complement inhibition dampens the inflammation during COVID‐19	36
Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents	35
Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia	35
A left shift in the oxyhaemoglobin dissociation curve in patients with severe coronavirus disease 2019 (COVID‐19)	35
Physiological and pathophysiological mechanisms of hepcidin regulation: clinical implications for iron disorders	35
Haematological management of major haemorrhage: a British Society for Haematology Guideline	34
Anti‐A isohaemagglutinin titres and SARS‐CoV‐2 neutralization: implications for children and convalescent plasma selection	34
Immune thrombocytopenic purpura after SARS‐CoV‐2 vaccine	34
Incidence and survival of multiple myeloma: a population‐based study of 10 524 patients diagnosed 1982–2017	34
The prevention of central nervous system relapse in diffuse large B‐cell lymphoma: a British Society for Haematology good practice paper	34
Risk factors for a severe form of COVID‐19 after allogeneic haematopoietic stem cell transplantation: a Société Francophone de Greffe de Moelle et de Thérapie cellulaire (SFGM‐TC) multicentre cohort s	34
C1 esterase inhibitor and the contact system in COVID‐19	34
Interleukin‐1 blockade with anakinra in acute leukaemia patients with severe COVID‐19 pneumonia appears safe and may result in clinical improvement	34
Arterial thromboembolic complications in COVID‐19 in low‐risk patients despite prophylaxis	33
Thrombocytopenia as an initial manifestation of COVID‐19; case series and literature review	33
Identification of CXCL12‐abundant reticular cells in human adult bone marrow	33
Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis	33
Haemoglobin oxygen affinity in patients with severe COVID‐19 infection	33
Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID‐19 vaccine in haemato‐oncological patients with no antibody response	33
Patients with sickle cell disease and suspected COVID‐19 in a paediatric intensive care unit	33
A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia	33
Integrating germline variant assessment into routine clinical practice for myelodysplastic syndrome and acute myeloid leukaemia: current strategies and challenges	32
Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL‐class fusion	32
Ruxolitinib for tocilizumab‐refractory severe COVID‐19 infection	32
Anticoagulation with argatroban in patients with acute antithrombin deficiency in severe COVID‐19	32
Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndrome	31
Mantle cell lymphoma – advances in molecular biology, prognostication and treatment approaches	31
Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy	31
COVID‐19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B‐lymphocytosis; humoural and cellular immunity	31
How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML)	31
Thrombophilia testing: A British Society for Haematology guideline	30
Relative expansion of CD19‐negative very‐early normal B‐cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR‐T cell therapy: implications for flo	30
Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood	30
Diagnosis and management of Waldenström macroglobulinaemia—A British Society for Haematology guideline	30
Thrombosis in immune thrombocytopenia — current status and future perspectives	30
p53 is associated with high‐risk and pinpointsTP53missense mutations in mantle cell lymphoma	30
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study	30
Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real‐world analysis of outcomes in 211 patients	30
Pembrolizumab in relapsed or refractory Richter syndrome	29
Reactive lymphocytes in patients with COVID‐19	29
SARS‐CoV‐2 infection anxieties and general population restrictions delay diagnosis and treatment of acute haematological malignancies	29
Acquired severe aplastic anaemia: how medical therapy evolved in the 20th and 21st centuries	29
Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience	29
Abstracts	29
Amelioration of COVID‐19‐related cytokine storm syndrome: parallels to chimeric antigen receptor‐T cell cytokine release syndrome	29
Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease	29
Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1‐mutated acute myeloid leukaemia	29
Prevalence and mortality in β‐thalassaemias due to outbreak of novel coronavirus disease (COVID‐19): the nationwide Iranian experience	28
Clinical outcomes of IDH2‐mutated advanced‐phase Ph‐negative myeloproliferative neoplasms treated with enasidenib	28
Management of sickle cell disease in pregnancy. A British Society for Haematology Guideline	28
Application of the LymphGen classification tool to 928 clinically and genetically‐characterised cases of diffuse large B cell lymphoma (DLBCL)	28
6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival	28
Impaired antibody response to COVID‐19 vaccination in patients with chronic myeloid neoplasms	28
Triage tool for the rationing of blood for massively bleeding patients during a severe national blood shortage: guidance from the National Blood Transfusion Committee	28
Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials	28
New developments in von Willebrand disease	27
Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutations	27
Pathogenesis of follicular lymphoma: genetics to the microenvironment to clinical translation	27
More on ‘Association between ABO blood groups and risk of SARS‐CoV‐2 pneumonia’	27
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) wi	27
How we(’ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future	27
Lenalidomide and pomalidomide potently interfere with induction of myeloid‐derived suppressor cells in multiple myeloma	27
Temporal changes in immune blood cell parameters in COVID‐19 infection and recovery from severe infection	27
Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics	27
von Willebrand factor/ADAMTS13 axis and venous thromboembolism in moderate‐to‐severe COVID‐19 patients	27
Atypical lymphocytes in peripheral blood of patients with COVID‐19	26
Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non‐Hodgkin lymphoma	26
Allogeneic haematopoietic stem cell transplantation for VEXAS syndrome: UK experience	26
FDG‐PET/CT after two cycles of R‐CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute pro	26
Eltrombopag added to immunosuppression for children with treatment‐naïve severe aplastic anaemia	26

Managing sickle cell patients with COVID‐19 infection: the need to pool our collective experience	25
Varying presentations and favourable outcomes of COVID‐19 infection in children and young adults with sickle cell disease: an additional case series with comparisons to published cases	25
Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide	25
Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review	25
SARS‐CoV‐2: a new aetiology for atypical lymphocytes	25
Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study	25
Guideline for the laboratory diagnosis of iron deficiency in adults (excluding pregnancy) and children	25
Haematological cancers and the risk of severe COVID‐19: Exploration and critical evaluation of the evidence to date	25
Impact of major bleeding and thrombosis on 180‐day survival in patients with severe COVID‐19 supported with veno‐venous extracorporeal membrane oxygenation in the United Kingdom: a multicentre observa	25
Haemophagocytosis in bone marrow aspirates in patients with COVID‐19	25
Are mushroom‐shaped erythrocytes an indicator of COVID‐19?	24
The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T‐cell lymphoma	24
Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma	24
A universal anti‐Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation	24
Effect of low or high doses of low‐molecular‐weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVID‐19	24
COVID‐19 associated Kikuchi‐Fujimoto disease	24
Retention of functional mitochondria in mature red blood cells from patients with sickle cell disease	24
Immature platelets as a biomarker for disease severity and mortality in COVID‐19 patients	24
The role of high‐dose melphalan with autologous stem‐cell transplant in multiple myeloma: is it time for a paradigm shift?	23
Ruxolitinib‐combined doxorubicin‐etoposide‐methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single‐arm, multicentre, phase 2 trial	23
Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open‐label study	23
Abnormal concentration of porphyrins in serum from COVID‐19 patients	23
Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy	23
Zanubrutinib for treatment‐naïve and relapsed/refractory chronic lymphocytic leukaemia: long‐term follow‐up of the phase I/II AU‐003 study	23
Prognostic utility of a geriatric nutritional risk index in combination with a comorbidity index in elderly patients with diffuse large B cell lymphoma	23
Vasculo‐toxic and pro‐inflammatory action of unbound haemoglobin, haem and iron in transfusion‐dependent patients with haemolytic anaemias	22
Philadelphia‐positive acute lymphoblastic leukaemia (ALL) in Italy during the COVID‐19 pandemic: a Campus ALL study	22
Deficit of circulating CD19+CD24hiCD38hi regulatory B cells in severe aplastic anaemia	22
Eltrombopag second‐line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off‐treatment: results of a phase II, multicentre, prospective study	22
Rituximab‐treated patients with lymphoma develop strong CD8 T‐cell responses following COVID‐19 vaccination	22
Thrombolysis restores perfusion in COVID‐19 hypoxia	22
Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline	22
Absence of hydroxyurea‐induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia	22
Clinical significance of blue‐green neutrophil and monocyte cytoplasmic inclusions in SARS‐CoV‐2 positive critically ill patients	22
COVID‐19 infection in patients on anti‐complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience	22
Knowledge gaps in reproductive and sexual health in girls and women with sickle cell disease	21
Assessing the impact of lockdown: Fresh challenges for the care of haematology patients in the COVID‐19 pandemic	21
Favourable outcome of coronavirus disease 2019 in a 1‐year‐old girl with acute myeloid leukaemia and severe treatment‐induced immunosuppression	21
Adoptive immunotherapy with double‐bright (CD56bright/CD16bright) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof‐of‐concep	21
Inherited predisposition to haematopoietic malignancies: overcoming barriers and exploring opportunities	21
Thrombotic thrombocytopenic purpura temporally associated with BNT162b2 vaccination in an adolescent successfully treated with caplacizumab	21
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients	21
Reflection on passive immunotherapy in those who need most: some novel strategic arguments for obtaining safer therapeutic plasma or autologous antibodies from recovered COVID‐19 infected patients	20
Real‐world non‐interventional long‐term post‐authorisation safety study of ruxolitinib in myelofibrosis	20
Direct‐acting antiviral agents for hepatitis C virus‐mixed cryoglobulinaemia: dissociated virological and haematological responses	20
Interleukin 6‐blockade treatment for severe COVID‐19 in two patients with multiple myeloma	20
Third dose of COVID‐19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres	20
Safety of anti‐SARS‐CoV‐2 vaccination for patients with immune thrombocytopenia	20
Implications of detecting serum monoclonal protein by MASS‐fix following stem cell transplantation in multiple myeloma	20
Cerebral MRI findings predict the risk of cognitive impairment in thrombotic thrombocytopenic purpura	20
The NICE COVID‐19 rapid guideline on haematopoietic stem cell transplantation: development, implementation and impact	20
Gender‐related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes	20
Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID‐19: disease control as an important factor relative to recent chemotherapy or anti‐CD20 therapy	20
Allogeneic cord blood transfusions prevent fetal haemoglobin depletion in preterm neonates. Results of the CB‐TrIP study	20
Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Onc	20
Novel therapies for immune thrombocytopenia	19
Current and future therapies for haemophilia—Beyond factor replacement therapies	19
Second primary malignancy in myelofibrosis patients treated with ruxolitinib	19
The detection of circulating plasma cells may improve the Revised International Staging System (R‐ISS) risk stratification of patients with newly diagnosed multiple myeloma	19
Incorporating acalabrutinib, a selective next‐generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies	19
Plasma microparticles of intubated COVID‐19 patients cause endothelial cell death, neutrophil adhesion and netosis, in a phosphatidylserine‐dependent manner	19
Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS‐CoV‐2 infection	19
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand‐1 (PD‐L1) expression and increases anti‐tumour effects of T cells in multiple myeloma	19
Statin and cyclooxygenase‐2 inhibitors improve survival in newly diagnosed diffuse large B‐cell lymphoma: a large population‐based study of 4913 subjects	19
Glucocorticoid use and risk of first and recurrent venous thromboembolism: self‐controlled case‐series and cohort study	19
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B‐cell lymphoma patients treated in the FIL‐DLCL04 trial	19
Efficacy and safety of intravitreal methotrexate for vitreo‐retinal lymphoma – 20 years of experience	19
The role of eosinophil morphology in distinguishing between reactive eosinophilia and eosinophilia as a feature of a myeloid neoplasm	19
Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical Hodgkin lymphoma unsuita	19
Humoral response to mRNA‐based COVID‐19 vaccine in patients with myeloid malignancies	18
TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia	18
Serological response following BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccination in haematopoietic stem cell transplantation patients	18
Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita	18
CAR‐T TREK through the lymphoma universe, to boldly go where no other therapy has gone before	18
Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia	18
Pre‐treatment metabolic tumour volume and total lesion glycolysis are superior to conventional positron‐emission tomography/computed tomography variables for outcome prediction in patients with newly	18
Haemophilia: factoring in new therapies	18
Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials	18
Focus on monoclonal antibodies targeting B‐cell maturation antigen (BCMA) in multiple myeloma: update 2021	18
Rapid screening of COVID‐19 patients using white blood cell scattergrams, a study on 381 patients	18
Epstein–Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features	18
COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report	18
Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant	18
Impact of type of reduced‐intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma	18
Combined IL‐6 and JAK/STAT inhibition therapy in COVID‐19‐related sHLH, potential game changer	17
Paradoxical effect of SARS‐CoV‐2 infection in patients with immune thrombocytopenia	17
Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID‐19 pandemic	17
Second allogeneic haematopoietic cell transplantation using HLA‐matched unrelated versus T‐cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia	17
Prevalence of germline GATA2 and SAMD9/9L variants in paediatric haematological disorders with monosomy 7	17
Complement as the enabler of carfilzomib‐induced thrombotic microangiopathy	17
Treatment for pure red cell aplasia after major ABO‐incompatible allogeneic stem cell transplantation: a multicentre study	17
Donor source and post‐transplantation cyclophosphamide influence outcome in allogeneic stem cell transplantation for GATA2 deficiency	17
Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study	17
Checkpoint blockade treatment sensitises relapsed/refractory non‐Hodgkin lymphoma to subsequent therapy	17
Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study*	17